Over 50m people suffer from multimorbidity (PMM) in Europe. Recent reviews find that PMM experience a range of system and professional-related issues with care delivery. In part, this is because current investments in process-based delivery means delivering healthcare within single diagnoses tracks/silos. For PMMs this does not reflect real-world conditions. No technology is available today that enables the specific care, treatment, administration and support needed for this target group. Breakthrough solutions will classify the individual according to their co/multimorbidities and medications. But this needs to be developed in close dialogue between PMM, care providers and industry sectors based upon a strong demand driven approach in a PCP. Accordingly, the CareMatrix Buyers Group (SE, NO, ES) challenge the market to develop innovative technology that enables more predictive care and support benefits for PMM. This is achieved with 6 project objectives summarised as PCP: stakeholder engagement, roadmap, Call, implementation, next steps and; profiling and outreach via IFIC. The methodology can be summarised as PCP: framing actions (PCP preparation, use of UCD principles and practice); implementation actions (Phases 1-3 contract management, support, evaluation and testing) and Market Preparation actions (business development support for Phase 3 suppliers, standards, initial PPI preparation). Direct benefits include: • 20% reduction in time spent for visits to care facilities • Improvements from baseline in at least 75% of aspects of care as identified using PREM surveys • 50% fewer patient data-related incidents (increased patient safety) between organizations • No of clinical errors reduced by 30%; Underpinning the CareMatrix solution(s) with integrated innovation (supportive policy priorities, organisational and social innovations) will optimise the potential of those solutions to produce savings of 10% in health care expenditure for PMM.

Colorectal cancer represents around one tenth of all cancers worldwide. Early and accurate diagnosis and precise intervention can increase cure rate up to 90%. Improved diagnostic techniques with enough sensitivity and specificity are required to allow in situ assessment, safe characterization and resection of lesions during clinical practice interventions. The multidisciplinary PICCOLO team proposes a new compact, hybrid and multimodal photonics endoscope based on Optical Coherence Tomography (OCT) and Multi-Photon Tomography (MPT) combined with novel red-flag fluorescence technology for in vivo diagnosis and clinical decision support. By combining the outstanding structural information from OCT with the precise functional information from MPT, this innovative endoscope will provide gastroenterologists immediate and detailed in situ identification of colorectal neoplastic lesions and facilitate accurate and reliable in vivo diagnostics, with additional, grading capabilities for colon cancer as well as in-situ lesion infiltration and margin assessment. With the development of compact instrumentation, the cost of the components and thus the system will be significantly reduced. Human representative animal models will be used to generate imaging biomarkers that allow automated detection, assessment and grading of disease. The developed system will be tested in operating room conditions. The consortium comprises the whole value chain including pre-clinical and clinical partners, technology providers, photonics SMEs and endoscopy market leader company. The project will permit these companies to enhance their competitiveness and leadership in the diagnostics sector as well as exploiting new market opportunities. The new endoscope will significantly impact clinical practice allowing in vivo optical biopsy assessment via the automatic analysis of images allowing accurate and efficient characterisation of colorectal lesions.